Back to Agenda
Innovative Funding Models for Novel Therapeutics
Session Chair(s)
Dan Tierno, MA, MBA
Associate Director, Project and Portfolio Management, Daiichi Sankyo, Inc, United States
In the pharmaceutical and biotech industry today the scope for and the breadth of stakeholders is expanding. Today’s development networks are emerging as consortiums that freely share learnings and experiences in order to make the best therapeutic development strategies. Yet, there is still more to do to identify and leverage our available knowledge networks. In this forum we will focus on strategies to best collaborate for novel therapeutic development.
Additionally this forum will also cover specific product investing. Unlike healthcare technology, most angel investors categorically dismiss medical product investing – especially for drug products. There are ways to bridge this gap through better preparation and understanding. In this forum we will also discuss common threads of deals angels invest in, the ones they don’t and how they make those decisions. Items such as the product, the team, deal structure, expected return, time to return, drugs vs. devices, regulatory strategy and life cycle management.
Learning Objective : Discuss the thinking of angel investors from a large angel investing syndicate; Describe how to prepare your company for investor pitching; Evaluate the quality of interaction of stakeholders in cure-based development; Assess quality of those interactions of stakeholders in their own environment; Recognize the importance of fostering an environment of innovation and entrepreneurship.
Speaker(s)
Dan Tierno, MA, MBA
Associate Director, Project and Portfolio Management, Daiichi Sankyo, Inc, United States
David Vulcano, MBA, RAC
CEO, ACRP | Association of Clinical Research Professionals, United States
Steve Scott, RN
Independent Clinical Consultant, ResearchwoRx, United States
Have an account?